

Published in final edited form as:

Bioorg Med Chem Lett. 2011 May 1; 21(9): 2732–2735. doi:10.1016/j.bmcl.2010.11.104.

Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-Jun N-terminal kinase inhibitors

Romain Noël, Youseung Shin, Xinyi Song, Yuanjun He, Marcel Koenig, Weimin Chen, Yuan Yuan Ling, Li Lin, Claudia H. Ruiz, Phil LoGrasso, Michael D. Cameron, Derek R. Duckett, and Theodore M. Kamenecka

Department of Molecular Therapeutics and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA

Abstract

The design and synthesis of a novel series of c-jun N-terminal kinase (JNK) inhibitors is described. The development of the 4-(pyrazol-3-yl)-pyridine series was discovered from an earlier pyrimidine series of JNK inhibitors. Through the optimization of the scaffold **2**, several potent compounds with good *in vivo* profiles were discovered.

Protein kinases catalyse the phosphorylation of tyrosine and serine/threonine residues in proteins involved in the regulation of diverse cellular functions. Aberrant kinase activity is implicated in many diseases, which makes the inhibition of kinases an attractive target for the pharmaceutical industry [1]. As a member of the mitogen-activated protein kinase (MAPK) family, the c-Jun N-terminal kinases (JNKs) regulate the serine/threonine phosphorylation of several transcription factors when they are activated in response of a variety of stress-based stimuli such as cytokines, ultraviolet irradiation, heat shock, fatty acids and osmotic shock [2, 3]. Three distinct genes (*jnk1*, *jnk2* and *jnk3*) encoding the ten splice variants of JNK (JNK1 α 1, JNK1 β 1, JNK1 α 2, JNK1 β 2; JNK2 α 1, JNK2 β 1, JNK2 α 2, JNK2 β 2; JNK3 α 1, JNK3 α 2) have been identified [4]. These isoforms differ in their tissue distribution profile and functions, with JNK1 and JNK2 being ubiquitously expressed, whereas JNK3 is expressed predominantly in the brain and at lower levels in the heart and testis [5, 6].

In recent studies, JNK-1, often in concert with JNK-2, has been suggested to play a central role in the development of obesity-induced insulin resistance which implies therapeutic inhibition of JNK1 may provide a potential solution in type-2 diabetes mellitus [7, 8]. JNK2 has been described in the pathology of autoimmune disorders such as rheumatoid arthritis and asthma, and it also has been implicated to play a role in cancer, as well as in a broad range of diseases with an inflammatory component [9–13]. JNK3 has been shown to play important roles in the brain to mediate neurodegeneration, such as beta amyloid processing, Tau phosphorylation and neuronal apoptosis in Alzheimer's disease, as well as the mediation of neurotoxicity in a rodent model of Parkinson's disease [14–16]. JNK3 is almost exclusively found in the brain. Identifying potent inhibitors of JNK3, with selectivity within the wider MAPK family (one of which is p38), may contribute towards neuroprotection therapies with reduced side effect profiles.

Therefore, developing JNK inhibitors as therapeutics has gained considerable interest over the past few years [17–32]. As part of our medicinal chemistry research program, we initiated a JNK3 project with a key objective of identifying brain penetrant compounds with

good JNK3 potency and selectivity over p38. We previously reported on the synthesis and SAR of 4-phenyl substituted pyrimidines [31]. Compounds in this class had good *in vitro* potency, but only modest *in vivo* profiles (rodent pk and brain penetration). In the continuous development and optimization of JNK3 inhibitors, we found 4-pyrazole substituted pyrimidines were also potent inhibitors [33]. The first synthesized 4-(pyrazol-3-yl)-pyrimidine, compound **1**, inhibited JNK3 with an $IC_{50} = 0.63 \mu M$ with no detectable inhibition of p38 ($> 20 \mu M$). Encouraged by the JNK3 potency and selectivity against p38, we initiated a structure-activity relationships (SAR) study [34]. Our strategy was based on scaffold **2** and more precisely on the maintenance of the core structure of **1** wherein we could vary either X, Y, R^1 , R^2 and R^3 groups by modification or introduction of substituents.

The analogues **7–9** were synthesized from compound **3** or **5** as described in Scheme 1 and data is shown in Table 1 [35]. The 2- and 4-positions of pyrimidine **3** were subsequently replaced with a substituted aniline and a chlorine atom to afford intermediate **4**. The pyrazole ring was introduced *via* a Suzuki coupling to give compounds **7** with $R^1 = H$. N-alkylation with alkyl halides gave **7** with $R^1 = \text{alkyl}$. The analogues **8** were synthesized from compound **5** in 5 steps. Stille coupling of trichloropyrimidine **5** followed by hydrolysis afforded ketone **6**. Introduction of the aniline followed by pyrazole ring formation via a two-step procedure gave compounds **8–9**.

Unfortunately, compounds containing pyrrazoles bearing free NH's had poor brain penetration. To decrease the polarity of our lead compounds, and hopefully improve brain penetration, the nitrogen atom of the pyrazole ring was alkylated with a methyl group. This led to a decrease in JNK3 inhibition to $1.45 \mu M$ for **7** (Table 1). The introduction of a 5-chloro group on the pyrimidine ring recovered some of the potency (**8**) lost by N-alkylation. We also found that modification of the R^2 substituent did little in the way of improving inhibition (ie: **9**), but did play a role in modulating *in vivo* parameters.

In the literature, kinase inhibitors with a central pyrimidine core are ubiquitous whereas those containing pyridine cores are far less common [33, 36–41]. With intermediates in hand, we decided to investigate if 4-pyrazole substituted pyridines had any activity against JNK3. Additionally, removing one heteroatom from the pyrimidine core would further reduce polarity. Pyridine analogues were synthesized as described in Scheme 2.

The halogenated pyridine **10** was coupled with pyrazole boronic acid to give **11**. Anilines were introduced into the 2-position via Buchwald-Hartwig conditions to afford compounds **12–13** with a hydrogen atom as the R^1 substituent [42]. Compounds **14–23** were synthesized by N-alkylation ($R^1 = \text{alkyl}$) or by a variation of the Ullmann reaction ($R^1 = \text{aryl}$), followed by a Buchwald-Hartwig reaction. The rapid synthesis of these compounds allowed us to evaluate a series of analogues with a variety of substituents (not all data shown). Of all R^2 substituents examined, only a few (A-F) are presented here (Figure 2).

Surprisingly, pyridine containing compounds were more potent than their corresponding pyrimidine analogues (Table 2). Compound **12** with no substitution at the 1-position on the pyrazole ring or at the 5-position on the pyridine ring had an IC_{50} value 160 nM for the inhibition of JNK3 with no detectable activity against p38. The introduction of a chlorine atom at C-5 (X substituent in **13**) provided a 2-fold boost in activity. Unfortunately, the N-alkylation of the pyrazole nitrogen (**14**) led to a slight decrease in potency which is a tradeoff as it also serves to reduce compound polarity. Once again, modification of the aniline substituent provided no advantage with regards to *in vitro* potency. A 5-fluoro substituent (**18**) was equipotent to the 5-chloro (**14**) substituted compound. Substitution at

C-5 with a methyl group (**23**) led to a 4-fold drop in potency (**23** versus **16** and **22**). Fortunately, all analogs tested showed no inhibition against p38.

Surprisingly, the phenyl ring in the aniline did not tolerate substitution, as both fluoro-substituted analogues were inactive against JNK3 ($> 20 \mu\text{M}$) (Figure 3, compounds **24** and **25**). Additionally, 1-methyl-5-pyrazole isomers **26–28** (JNK3 IC_{50} 1.6 μM , 6.0 μM and 6.2 μM , respectively) were considerably less potent JNK inhibitors than their corresponding 1-methyl 3-pyrazole isomers (**14** and **18**).

We then looked to optimize pyrazole substitution (R^1) as a means to improve JNK3 inhibition (Table 3). Compound **29** with an N-benzyl group was slightly more potent than **18** ($\text{R}^1 = \text{Me}$). Phenethyl substitution (**30**) led to a slight decrease in potency. The morpholino-ethyl group was also less active (compound **31**). The introduction of substituted aromatic rings (**32–35**) also led to a drop in JNK potency depending on substitution.

We next investigated substitution at the 4-position on the pyrazole ring (Table 4, R^3). To facilitate SAR of the R^3 substituent, we chose to use an N-methyl as the R^1 substituent, and dimethyltriazole or morpholine (respectively noted D and E) as the R^2 substituent.

The synthesis of analogues (**37–43**) is outlined in Scheme 2. Compound **36** was obtained in two steps *via* a Suzuki coupling followed by N-alkylation. The regioselective bromination of the pyrazole ring at the 4-position, followed by another Suzuki coupling allowed for the introduction of R^3 -substituents [43]. The last step was the introduction of the substituted aniline under acidic conditions which provided the desired compounds.

Interestingly, 4-fluorophenyl substitution (**37**) resulted in a big boost in JNK3 potency concomitant with the loss of the selectivity between JNK3 and p38. This was true for several other phenyl substituted analogues (not shown). Heterocyclic rings did not afford the magnitude of potency enhancement that came with phenyl or substituted phenyl rings (**38–41**). However, it was interesting that pyrazole substitution, and smaller alkyl groups did not pick up p38 activity, although JNK activity also decreased.

Several compounds from this series were analyzed *in vivo* (Table 5) [44]. The compounds with morpholine as a R^2 substituent (E) suffer from poor pharmacokinetics (high clearance, short half-life and low bioavailability). For the other R^2 substituents, the compounds had a much improved *in vivo* profile (low clearance, good half-life and very good bioavailability). For most compounds tested in this series, the blood brain barrier penetration was also quite good (30–100%).

In summary, a novel series of pyrazole substituted pyrazoles has been developed. Optimization of this scaffold by modification of five substituents (X, Y R^1 , R^2 and R^3) afforded a series of potent JNK3 inhibitors free of p38 inhibition. Several compounds from this class have good pharmacokinetics and brain penetration. Evaluation of compounds of this type *in vivo* in CNS models of human disease (Parkinson's and Alzheimer's disease, stroke) is ongoing and will be reported in due course.

References and notes

1. Parang K, Sung GQ. Design strategies for protein kinase inhibitors. *Current Opinion in Drug Discovery & Development*. 2004; 7(5):617–629.
2. Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). *International Journal of Biochemistry & Cell Biology*. 2001; 33(11): 1047–1063. [PubMed: 11551821]

3. Weston CR, Davis RJ. The JNK signal transduction pathway. *Current Opinion in Cell Biology*. 2007; 19(2):142–149. [PubMed: 17303404]
4. Gupta S, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. *Embo Journal*. 1996; 15(11):2760–2770. [PubMed: 8654373]
5. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiological Reviews*. 2001; 81(2):807–869. [PubMed: 11274345]
6. Morrison DK, Davis RJ. Regulation of map kinase signaling modules by scaffold proteins in mammals. *Annual Review of Cell and Developmental Biology*. 2003; 19:91–118.
7. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. *Nature*. 2002; 420(6913):333–336. [PubMed: 12447443]
8. Bennett BL, Satoh Y, Lewis AJ. JNK: a new therapeutic target for diabetes. *Current Opinion in Pharmacology*. 2003; 3(4):420–425. [PubMed: 12901952]
9. Han ZN, et al. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. *Arthritis and Rheumatism*. 2002; 46(3):818–823. [PubMed: 11920420]
10. Wong WSF. Inhibitors of the tyrosine kinase signaling cascade for asthma. *Current Opinion in Pharmacology*. 2005; 5(3):264–271. [PubMed: 15907913]
11. Pelaia G, et al. Mitogen-activated protein kinases and asthma. *Journal of Cellular Physiology*. 2005; 202(3):642–653. [PubMed: 15316926]
12. Blease K, Lewis A, Raymon HK. Emerging treatments for asthma. *Expert Opin Emerg Drugs*. 2003; 8(1):71–81. [PubMed: 14610913]
13. Zhang H, et al. Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. *Journal of Biological Chemistry*. 2002; 277(46):43648–58. [PubMed: 12221076]
14. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. *Drug Discov Today*. 2004; 9(21):932–9. [PubMed: 15501728]
15. Kimberly WT, et al. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. *J Neurosci*. 2005; 25(23):5533–43. [PubMed: 15944381]
16. Pan J, et al. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways. *Mol Pharmacol*. 2007; 72(6):1607–18. [PubMed: 17855652]
17. Bennett BL, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. *Proc Natl Acad Sci U S A*. 2001; 98(24):13681–6. [PubMed: 11717429]
18. Ruckle T, et al. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminoethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. *Journal of Medicinal Chemistry*. 2004; 47(27):6921–34. [PubMed: 15615541]
19. Graczyk PP, et al. The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. *Bioorganic & Medicinal Chemistry Letters*. 2005; 15(21):4666–70. [PubMed: 16153829]
20. Gaillard P, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. *Journal of Medicinal Chemistry*. 2005; 48(14):4596–607. [PubMed: 15999997]
21. Swahn BM, et al. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. *Bioorganic & Medicinal Chemistry Letters*. 2005; 15(22):5095–9. [PubMed: 16140012]
22. Stocks MJ, et al. Structure-driven HTL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. *Bioorganic & Medicinal Chemistry Letters*. 2005; 15(14):3459–62. [PubMed: 15950471]
23. Swahn BM, et al. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. *Bioorganic & Medicinal Chemistry Letters*. 2006; 16(5):1397–401. [PubMed: 16337120]

24. Angell RM, et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. *Bioorganic & Medicinal Chemistry Letters*. 2007; 17(5):1296–301. [PubMed: 17194588]
25. Alam M, et al. Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. *Bioorganic & Medicinal Chemistry Letters*. 2007; 17(12):3463–7. [PubMed: 17459703]
26. Christopher JA, et al. 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3. *Bioorganic & Medicinal Chemistry Letters*. 2009; 19(8):2230–4. [PubMed: 19303774]
27. Cao J, et al. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors. *Bioorganic & Medicinal Chemistry Letters*. 2009; 19(10):2891–5. [PubMed: 19361991]
28. Jiang R, et al. 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. *Bioorganic & Medicinal Chemistry Letters*. 2007; 17(22):6378–82. [PubMed: 17911023]
29. Shin Y, et al. Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. *Bioorganic & Medicinal Chemistry Letters*. 2009; 19(12):3344–7. [PubMed: 19433357]
30. Kamenecka T, et al. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. *Journal of Biological Chemistry*. 2009; 284(19):12853–61. [PubMed: 19261605]
31. Kamenecka T, et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. *Journal of Medicinal Chemistry*. 2010; 53(1):419–31. [PubMed: 19947601]
32. LoGrasso P, Kamenecka T. Inhibitors of c-jun-N-terminal kinase (JNK). *Mini Rev Med Chem*. 2008; 8(8):755–66. [PubMed: 18673131]
33. WO. 0246184.
34. There is good selectivity when compounds show more than 100-fold selectivity for JNK3 over P38.
35. Biochemical Assays Measuring JNK Activity: Biochemical IC50s for JNK3 and p38 were determined using HTRF. Briefly, final assay concentrations of JNK3, biotinylated-ATF2 and ATP were 0.3nM, 0.4nM, and 1µM, respectively. Final assay concentrations of p38, biotinylated-ATF2, and ATP were 1nM, 0.4nM, and 11.5µM, respectively. In both assays, the phosphor- Thr71-ATF-2 product was detected by a Europiumcryptate-labeled anti-phospho-Thr71-ATF-2 antibody. Streptavidin-allophycocyanin -XL was used as the acceptor. A 10-point dose-response curve for each compound was generated in duplicate and data were fit to a four parameter logistic.
36. Burns CJ, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). *Bioorganic & Medicinal Chemistry Letters*. 2009; 19(20):5887–92. [PubMed: 19762238]
37. Aliagas-Martin I, et al. A class of 2,4-bisanilino-pyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. *Journal of Medicinal Chemistry*. 2009; 52(10):3300–7. [PubMed: 19402633]
38. WO. 2008129071.
39. WO. 2008099074.
40. WO. 2004084901.
41. Paul R, et al. Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors. *Journal of Medicinal Chemistry*. 1993; 36(19):2716–25. [PubMed: 8410986]
42. Janey JM. Buchwald-Hartwig Amination. *Name Reactions for Functional Group Transformations*. 2007:564–609.
43. Miyaura N, Suzuki A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. *Chemical Reviews*. 1995; 95(7):2457–2483.
44. Rat Pharmacokinetics and Mouse Brain Penetration: Pharmacokinetics of test compounds was assessed in Sprague-Dawley rats (n = 3). Compounds were dosed intravenously at 1 mg/kg and orally by gavage at 2 mg/kg. Blood was taken at eight time points (5, 15, 30 min, 1, 2, 4, 6, 8 h) and collected into EDTA containing tubes and plasma was generated using standard centrifugation techniques. Plasma proteins were precipitated with acetonitrile and drug concentrations were determined by LC-MS/MS. Data was fit by WinNonLin using a noncompartmental model and basic pharmacokinetic parameters including peak plasma concentration (Cmax), oral bioavailability, exposure (AUC), half-life (t1/2), clearance (CL), and volume of distribution (Vd)

were calculated. CNS exposure was evaluated in C57Bl6 mice (n = 3). Compounds were dosed at 10 mg/kg intraperitoneally and after 2 h blood and brain were collected. Plasma was generated and the samples were frozen at -80°C . The plasma and brain were mixed with acetonitrile (1:5 v:v or 1:5 w:v, respectively). The brain sample was sonicated with a probe tip sonicator to break up the tissue, and samples were analyzed for drug levels by LCMS/MS. Plasma drug levels were determined against standards made in plasma and brain levels against standards made in blank brain matrix. All procedures were approved by the Scripps Florida IACUC.




Figure 1.
Pyrazole pyrimidine JNK inhibitors




Figure 2.
R² substituents







Figure 3.
Additional pyrazole JNK inhibitors.

**Scheme 1.**

Reagents: a) R^2PhNH_2 , $\text{EtO}(\text{CH}_2)_2\text{OH}$, 75°C , 16h; b) conc. HCl , 90°C , overnight; POCl_3 , 100°C ; c) 3-pyrazoleboronic acid, $\text{Pd}(\text{PPh}_3)_4$, K_2CO_3 , $\text{DME}/\text{H}_2\text{O}$, 140°C , 1h, microwave; d) MeI , K_2CO_3 , DMF , 50°C , overnight; e) Tributyl(1-ethoxyvinyl)tin, $\text{Pd}(\text{PPh}_3)_4$, toluene, 125°C , 1.5h, microwave; f) conc. HCl , THF , 2h, rt; g) R^2PhNH_2 , $\text{EtO}(\text{CH}_2)_2\text{OH}/\text{H}_2\text{O}$, 120°C , 15h; h) *N,N*-dimethylformamide dimethylacetal, 110°C , overnight; i) MeNHNH_2 , EtOH , rt, 55h.

**Scheme 2.**

Reagents: a) 3-pyrazoleboronic acid, $\text{Pd}(\text{PPh}_3)_4$, K_2CO_3 , DMF, 100°C , 3h; b) MeI, K_2CO_3 , DMF, 50°C , overnight; or Ar^1X , CuI, K_2CO_3 , *trans*-*N,N'*-dimethylcyclohexane-1,2-diamine, dioxane, 120°C , overnight; c) R^2PhNH_2 , $\text{Pd}(\text{OAc})_2$, xantphos, Cs_2CO_3 , dioxane, 130°C , 1h, microwave.

**Scheme 3.**

Reagents: a) 3-pyrazoleboronic acid, Pd(PPh₃)₄, K₂CO₃, DMF, 100°C, 3h; b) MeI, K₂CO₃, DMF, 50°C, overnight; c) NBS, DMF, 50°C, 4h; d) R³B(OH)₂, Pd(PPh₃)₄, K₂CO₃, DME/H₂O, 100°C, 1h, microwave; e) R²PhNH₂, HCl(1M)/H₂O/dioxane (ratio 2/4/1).

Table 1

JNK3 inhibition by analogues of **7–9**.

| Comps | X | R ¹ | R ² | JNK3 IC ₅₀ (μM) ^a | p38 IC ₅₀ (μM) ^a |
|----------|----|----------------|----------------|-----------------------------------------|----------------------------------------|
| 1 | H | H | A | 0.63 | > 20 |
| 7 | H | Me | A | 1.45 | nt |
| 8 | Cl | Me | A | 0.86 | nt |
| 9 | Cl | Me | B | 0.73 | nt |

^aValues are means of three experiments, nt = not tested, All standard deviation ≤ 20%

Table 2


Inhibition of JNK3 by compounds **12–23**.

| Comps | X | R ¹ | R ² | JNK3 IC ₅₀ (μM) ^a | p38 IC ₅₀ (μM) ^a |
|-----------|----|----------------|----------------|-----------------------------------------|----------------------------------------|
| 12 | H | H | E | 0.16 | >20 |
| 13 | Cl | H | E | 0.07 | >20 |
| 14 | Cl | Me | E | 0.13 | >20 |
| 15 | Cl | Me | D | 0.16 | >20 |
| 16 | Cl | Me | B | 0.20 | >20 |
| 17 | Cl | Me | C | 0.60 | >20 |
| 18 | F | Me | E | 0.16 | >20 |
| 19 | F | Me | D | 0.34 | >20 |
| 20 | F | Me | C | 0.20 | >20 |
| 21 | F | Me | F | 0.48 | >20 |
| 22 | F | Me | B | 0.16 | >20 |
| 23 | Me | Me | B | 0.75 | >20 |

^a Values are means of three experiments. All standard deviation ≤ 20%

Table 3




Inhibition of JNK3 by compounds 29–35.

| Comps | X | R ¹ | R ² | JNK3 IC ₅₀ (μM) ^a | p38 IC ₅₀ (μM) ^a |
|-------|---|-------------------------------------------------------------------------------------|----------------|-----------------------------------------|----------------------------------------|
| 29 | F | Bn | E | 0.10 | >20 |
| 30 | F | (CH ₂) ₂ Ph | E | 0.17 | >20 |
| 31 | F |  | E | 0.32 | >20 |
| 32 | H | 3-MeOPh | D | 0.65 | >20 |
| 33 | H | 3-CNPh | D | 0.24 | >20 |
| 34 | H | 4-MeSPh | D | 1.33 | >20 |
| 35 | H | 2-Py | D | 0.34 | >20 |

^aValues are means of three experiments. All standard deviation ≤ 20%

Table 4

4-substituted pyrazole SAR

| Comps | R ² | R ³ | JNK3 IC ₅₀ (μM) ^a | p38 IC ₅₀ (μM) ^a |
|-------|----------------|------------------------------------------------------------------------------------|-----------------------------------------|----------------------------------------|
| 37 | D | 4-FPh | 0.007 | 0.02 |
| 38 | D | 3-Py | 0.11 | 1.14 |
| 39 | E |  | 0.15 | 0.19 |
| 40 | E |  | 0.39 | > 20 |
| 41 | E |  | 0.39 | > 20 |
| 42 | D | <i>n</i> -Pr | 1.40 | > 20 |
| 43 | D | Me | 0.40 | > 20 |

^aValues are means of three experiments, All standard deviation ≤ 20%

Table 5

Key brain penetration and pharmacokinetic parameters.

| Cmpds | Drug concentration (µM) ^a | Plasma/brain | Clp (mL/min/kg) ^b | t _{1/2} ^b | Oral AUC (µM.h) ^b | %F ^b |
|-------|--------------------------------------|--------------|------------------------------|-------------------------------|------------------------------|-----------------|
| 15 | 10.4/5.3 | | 9.0 | 1.3 | 7.1 | 73 |
| 16 | 6.6/3.5 | | 0.9 | 6.5 | 45 | 75 |
| 20 | 9.0/10.3 | | 4.2 | 2.3 | 10 | 69 |
| 21 | 3.3/0.74 | | 4.0 | 3.4 | 14.9 | 73 |
| 37 | 9.0/1.4 | | 6.4 | 1.5 | 6 | 51 |

^a mouse; 10mg/kg IP, 2h

^b rat; 1mg/kg IV; 2mg/kg PO